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Purpose: The validation of tumor, node, metastasis staging system
in terms of prognosis is an indispensable part of establishing a better
staging system in lung cancer.
Methods: In 2005, 387 Japanese institutions submitted informa-
tion regarding the prognosis and clinicopathologic profiles of
patients who underwent pulmonary resections for primary lung
neoplasms in 1999 to the Japanese Joint Committee of Lung
Cancer Registry. The data of 13,010 patients with only lung car-
cinoma histology (97.6%) were analyzed in terms of prognosis and
clinicopathologic characteristics.
Results: The 5-year survival rate of the entire group was 61.4%.
For the small cell histology (n  390), the 5-year survival rates
according to clinical (c) and pathologic (p) stages were as
follows: 58.8% (n  161) and 58.3% (n  127) for IA, 58.0%
(n  77) and 60.2% (n  79) for IB, 47.1% (n  17) and 40.6%
(n  29) for IIA, 25.3% (n  38) and 41.1% (n  29) for IIB,
29.0% (n  61) and 28.3% (n  60) for IIIA, 36.3% (n  19) and
34.6% (n  40) for IIIB, and 27.8% (n  12) and 30.8% for IV
(n  13). For the non-small cell histology (n  12,620), the
5-year survival rates according to c-stage and p-stage were as
follows: 77.3% (n  5642) and 83.9% (n  4772) for IA, 59.8%
(n  3081) and 66.3% (n  2629) for IB, 54.1% (n  205) and
61.0% (n  361) for IIA, 43.9% (n  1227) and 47.4% (n 
1330) for IIB, 38.3% (n  1628) and 32.8% (n  1862) for IIIA,
32.6% (n  526) and 29.6% (n  1108) for IIIB, and 26.5% (n 
198) and 23.1% (n  375) for IV. Adenocarcinoma, female
gender, and age less than 50 years were significant favorable
prognostic factors.
Conclusion: This large registry study provides benchmark prognos-
tic statistics for lung cancer. The prognostic difference between
stages IB and IIA was small despite different stages. Otherwise, the
present tumor, node, metastasis staging system well characterizes
the stage-specific prognoses.
Key Words: Lung cancer, Surgery, Prognosis, TNM stage, Resec-
tion, Cancer registry.
(J Thorac Oncol. 2008;3: 46–52)
The newly revised version of the Union InternationaleContre le Cancer tumor, node, metastasis (TNM) staging
system is to be promulgated for general use in 2009. The
present TNM staging system for lung cancer has been avail-
able worldwide since 1978,1 and the revision process is
underway. To establish a more sophisticated, truly prognostic
staging system, the validation of the existing system as well
as the simulation of the proposed revision based on a large,
updated data set are indispensable.
In Japan, the three major societies that deal with patients
with lung neoplasms, the Japan Lung Cancer Society, the Jap-
anese Association for Chest Surgery, and the Japanese Respira-
tory Society, established a task force committee (The Japanese
Joint Committee of Lung Cancer Registry) to perform a nation-
wide registry study on the prognosis and clinicopathologic
profiles of lung neoplasms, both retrospectively and prospec-
tively. The prospective follow-up registry study has been under-
way for all lung cancer patients who newly visited the hospital
in 2002. This prospective registry study includes both resected
and nonresected cases. Beside this, the committee has periodi-
cally performed three separate retrospective studies focused on
cases resected in the years 1989, 1994, and 1999 after a 5-year
follow-up period. These studies were planned at 5-year intervals
to observe changes and trends in the prognosis, staging, histo-
logic distribution, etc. of resected lung cancer patients in Japan.
The results of the second study for patients who were resected in
1994 have already been published elsewhere2 together with our
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proposal for possible revisions to the present staging system.3
The current study deals with third retrospective registry for
patients who were resected in 1999.
Therefore, the purpose of the present study was to
provide the most up-to-date benchmark statistics on the
prognosis of resected lung cancer, and to clarify the appro-
priateness and insufficiencies of the present TNM staging
system for lung cancer.
PATIENTS AND METHODS
Registry
In 2005, the Japanese Joint Committee of Lung Cancer
Registry performed a nationwide retrospective registry study
on the prognosis and clinicopathologic profiles of resected
primary lung neoplasms in Japan. Only primary lung neo-
plasms that had been resected in 1999 at the certified teaching
hospitals in Japan were considered for the registry, which had
a follow-up period of at least 5 years. The Committee received
the registries of 13,344 patients from 387 teaching hospitals. The
questionnaire included 32 items such as gender, age, clinical
(c)-T, c-N, c-M, c-stage, preoperative treatment, surgical proce-
dure, extent of lymph node dissection, curability, residual tumor,
primary site by lobe, tumor diameter, histology, organ invasion,
pathologic (p)-T, p-N, p-M, p-stage, pleural involvement, pleu-
ral dissemination, intrapulmonary metastasis, pleural cytology,
location of nodal metastasis, survival time, recurrence, and cause
of death. Recurrent or multiple lung cancers were not included in
this registry. The c-stage and p-stage were based on the 6th
edition of the Union Internationale Contre le Cancer-TNM
staging system published in 1997.1 The histology of the tumor
was described according to the World Health Organization
classification.4
Patients
Sixty-nine patients (0.5%) with incomplete descriptions
of their tumor histology and 265 patients with low-malignant
histology or nonepithelial tumor histology (2.0%) were ex-
cluded from the study. Therefore, the present study focused
on the remaining 13,010 patients with adenocarcinoma, squa-
mous cell carcinoma, small cell carcinoma, large cell carci-
noma, or adenosquamous carcinoma. The surgical resections
for these patients were various in terms of surgical mode,
level of lymph node exploration, and curability. Especially,
the resection was either complete in 11,528 patients (88.6%)
or incomplete in 1108 patients (8.5%), and the curability was
not clearly described in 374 patients (2.9%). Despite these,
the TNM staging of each patient was determined on the basis
of best available information before, during, and after surgi-
cal resections.
Statistical Analysis
The survival time was defined as the time from the date
of surgery to the last follow-up date. The survival curves
were estimated by the Kaplan-Meier method, and the differ-
ence in survival was tested by the log-rank test in which a
p value of less than 0.05 was considered significant.
RESULTS
For 13,010 registered patients with lung cancer, the
most common histologic type was adenocarcinoma in 8239
patients (63.3%) followed by squamous cell carcinoma in
3700 patients (28.4%), large cell carcinoma in 474 patients
(3.6%), small cell carcinoma in 390 patients (3.0%), and
adenosquamous carcinoma in 207 patients (1.6%). The sur-
vival curve of the entire registry population is shown in
Figure 1, in which the 5-year survival rate was 61.4%. The
survival curves according to histologic type of all stages are
shown in Figure 2. The 5-year survival rates according to the
histologic type were as follows: 67.3% for adenocarcinoma,
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FIGURE 1. A survival curve for all histologic types and all
stages (n  13,010). The 5-year survival rate for the entire
group is 61.4%.
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FIGURE 2. Survival curves according to histologic type. The
5-year survival rates according to histologic type are as fol-
lows: 67.3% for adenocarcinoma (n  8239), 52.5% for
squamous cell carcinoma (n  3700), 48.1% for small cell
carcinoma (n  390), 45.5% for large cell carcinoma (n 
474), and 42.1% for adenosquamous carcinoma (n  207).
There is a significant difference in survival between adeno-
carcinoma and others (p  0.0000). AD, adenocarcinoma;
SQ, squamous cell carcinoma; SM, small cell carcinoma; LG,
large cell carcinoma; AS, adenosquamous carcinoma.
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52.5% for squamous cell carcinoma, 48.1% for small cell
carcinoma, 45.5% for large cell carcinoma, and 42.1% for
adenosquamous carcinoma. The adenocarcinoma histology
had significantly better survival than other histologic types
(p  0.0000 each). Female patients comprised 32.5% (n 
4228) of the entire registered population, and male patients
comprised 66.6% (n 8664). The 5-year survival rates of the
female and male patients were 74.1% and 55.2%, respec-
tively. These survival curves are shown in Figure 3, and the
difference in survival between the 2 genders was significant
(p  0.0000). The clinical profiles and stage-specific prog-
nosis were described separately for small cell and non-small
cell histologic categories because of the known differences in
the pathobiologic nature and response to treatment between
these malignancies.
Small Cell Carcinoma
For 390 patients with resected small cell carcinoma of
all stages, the 5-year survival rate was 48.6%. The survival
curves according to stage are shown in Figure 4. The distri-
bution of c-stage and p-stage, stage-specific 5-year survival
rates, and the difference in survival between neighboring
stages are presented in Table 1.
Non-small Cell Carcinoma
For 12,620 patients with resected non-small cell histol-
ogies of all stages, the 5-year survival rate was 61.8%. The
survival curves according to stage are shown in Figure 5. The
distribution of c-stage and p-stage, stage-specific 5-year sur-
vival rates, and difference in survival between neighboring
stages are presented in Table 2. For the c-stage, the difference
in survival was significant between all neighboring c-stages
except for those between stages IB and IIA and between IIIA
and IIIB. For the p-stage, the difference in survival was
significant between all neighboring stages, although the dif-
ference between p-stages IB and IIA was approaching the
marginal significance level.
Survival was further analyzed according to patient age.
The survival curves according to three age groups, those50
years (n  797), those 50 years but 70 years (n  6563),
and those 70 years (n  5147) are shown in Figure 6. The
5-year survival rates for the three age groups were 69.9, 66.0,
and 54.9%, respectively. The survival of patients aged 70
years was significantly worse than those in the other two age
groups (p  0.0000 and p  0.0000).
Comparison between the 1994 and 1999
Registry Studies
The distribution of histologic types was compared be-
tween 1994 and 1999 (Fig. 7). Within the 5-year interval,
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FIGURE 3. Survival curves according to gender. The 5-year
survival rates of female (n  4228) and male (n  8664)
patients are 74.1% and 55.2%, respectively. The survival of
female patients is significantly better than that of male pa-
tients (p  0.0000).
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FIGURE 4. Survival curves of small cell lung carcinoma can-
cers according to c-stage (A) and p-stage (B) (n  390). The
5-year survival rates by c-stage are as follows: 58.8% for IA
(n  161), 58.0% for IB (n  77), 47.1% for IIA (n  17),
25.3% for IIB (n  38), 29.0% for IIIA (n  61), 36.3% for
IIIB (n  19), and 27.8% for IV (n  12). The 5-year survival
rates by p-stage are as follows: 58.3% for IA (n  127),
60.2% for IB (n  79), 40.6% for IIA (n  29), 41.1% for IIB
(n  29), 28.3% for IIIA (n  60), 34.6% for IIIB (n  40),
and 30.8% for IV (n  13).
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incidence of adenocarcinoma increased 7%, from 56 to 63%,
whereas that of squamous cell carcinoma decreased 5%, from
33 to 28%. The proportion of other histologic types remained
almost unchanged. When the overall survival was compared,
an improvement of the 5-year survival rate from 52.0 to
61.4% was achieved for all histologic types, and from 52.6 to
61.8% for non-small cell carcinomas. The gender distribution
did not change remarkably between 1994 and 1999: female
patients comprised 29.9% of the all the registered patients in
1994, and 32.8% in 1999. Nevertheless, the difference in
survival according to gender grew within the 5-year interval:
the difference in the 5-year survival rate between women and
men was 13.2% in 1994, and 18.9% in 1999.
The stage distribution was compared in non-small cell
lung carcinoma between 1994 and 1999 (Fig. 8). The per-
centage of stages IA and IB increased 11%, from 59 to 70%,
in the c-setting, and 8%, from 51 to 59%, in the p-setting.
Stage-specific 5-year survival rates in non-small cell carci-
noma were compared between the 1994 and 1999 registry
studies for c-stage (Table 3) and for p-stage (Table 4).
Although a survival improvement was achieved in all stages,
the change in stage IB was remarkable. The 5-year survival
rate in stage IB improved from 49.9 to 59.8% in a c-setting,
and from 60.1 to 66.3% in a p-setting. Summarizing these, the
trends from 1994 to 1999 consisted of an increase in the
adenocarcinoma histology and earlier stages, and an improve-
ment in the overall as well as the stage-specific survival.
DISCUSSION
This is a report on the third nationwide registry study
conducted by the Japanese Joint Committee of Lung Cancer
Registry representing three major Japanese societies that deal
with patients with lung cancer, in which the clinicopathologic
features and prognosis of the resected lung cancer were
studied. Three registry studies have independently and peri-
odically focused on cases that were resected in the years
1989, 1994, and 1999 after a 5-year follow-up period. The
details of the second study involving cases resected in 1994
in which 7393 patients with primary lung neoplasms were
registered from 307 teaching hospitals in Japan have already
been published elsewhere.2,3 The number of registered pa-
tients in the third study (13,344 patients) was almost twice
that of the second study (7393 patients) with only a slight
increase in the number of participating institutions from 307
to 387. The number of cases registered from each institute
ranged from 1 to 212 cases, and 15 institutes registered more
than 100 cases. Considering that the total number of lung
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FIGURE 5. Survival curves of non-small cell histologies ac-
cording to c-stage (A) and p-stage (B) (n  12,620). The
5-year survival rates by c-stage are as follows: 77.3% for IA
(n  5642), 59.8% for IB (n  3081), 54.1% for IIA (n 
205), 43.9% for IIB (n  1227), 38.3% for IIIA (n  1628),
32.6% for IIIB (n  526), and 26.5% for IV (n  198). The
5-year survival rates by p-stage are as follows: 83.9% for IA
(n  4772), 66.3% for IB (n  2629), 61.0% for IIA (n 
361), 47.4% for IIB (n  1330), 32.8% for IIIA (n  1862),
29.6% for IIIB (n  1108), and 23.1% for IV (n  375).
TABLE 1. Stage-Specific 5-Yr Survival Rates for Small Cell Carcinoma According to the
Clinical and Pathological Settings (n  390)
Stage Settings
Stage
IA IB IIA IIB IIIA IIIB IV
Clinical, n (%) 161 (41.3) 77 (19.7) 17 (4.4) 38 (9.7) 61 (15.6) 19 (4.9) 12 (3.1)
5-Yr survival rate, % 58.8 58.0 47.1 25.3 29.0 36.3 27.8
Difference in survivala 0.5627 0.4110 0.1577 0.9807 0.7045 0.7265 —
Pathological, n (%) 127 (32.6) 79 (20.3) 29 (7.4) 29 (7.4) 60 (15.4) 40 (10.3) 13 (3.3)
5-Yr survival rate, % 58.3 60.2 40.6 41.1 28.3 34.6 30.8
Difference in survivala 0.9331 0.0415 0.8289 0.2300 0.5217 0.6115 —
a Significance of the difference in survival between neighboring (lower and next higher) stages (p value).
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cancer resections in Japan was approximately 30,000, these
registered cases are estimated to comprise 30 to 40% of the
total. The results of this registry study represent the findings
based on the largest series ever published.
There has been remarkable difference in survival be-
tween patients resected in 1994 and 1999, where the overall
survival rate at 5 years in the registry population improved
from 52.6 to 61.4%. The stage-specific survival also im-
proved. Because the survival improvement was achieved not
only in all stages but also in the entire population, this
improvement should not be interpreted as simply the result of
a stage migration phenomenon. The possible reasons for the
improvement might be refinements in the evaluation of sur-
gical candidates, advancements and improvement in treat-
ment, and the shift of the registry population toward more
curable lung cancer.
Refinement in the preoperative work-up for surgical
candidates may better identify patients with distant disease,
resulting in a better selection of patients for surgery. Never-
theless, except for an improvement in imaging diagnosis
techniques such as computed tomography (CT), the differ-
ence in the quality of preoperative work-up between 1994 and
1999 does not seem significant. Even in 1999, positron
emission tomography scans were not used as part of a routine
preoperative work-up in Japan. Therefore, the difference in
preoperative work-up does not seem to account for the
difference in survival between the years 1994 and 1999.
When looking at the changes in surgical interventions
for lung cancer patients in the 5 years between 1994 and
TABLE 2. Stage-Specific 5-Yr Survival Rates for Non-small Cell Carcinoma According to the Clinical and Pathological Settings
(n  12,620)
Stage Settings
Stage
IA IB IIA IIB IIIA IIIB IV
Clinical, n (%) 5642 (44.7%) 3081 (24.4%) 205 (1.6%) 1227 (9.7%) 1628 (12.9%) 526 (4.2%) 198 (1.6%)
5-Yr survival rate, % 77.3 59.8 54.1 43.9 38.3 32.6 26.5
Difference in survivala 0.0000 0.1444 0.0022 0.0013 0.0755 0.0111 —
Pathological, n (%) 4772 (37.8%) 2629 (20.8%) 361 (2.9%) 1330 (10.5%) 1862 (14.8%) 1108 (8.8%) 375 (3.0%)
5-Yr survival rate, % 83.9 66.3 61.0 47.4 32.8 29.6 23.1
Difference in survivala 0.0000 0.0367 0.0000 0.0000 0.0054 0.0001 —
a Significance of the difference in survival between neighboring (lower and next higher) stages (p value).
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FIGURE 7. Distribution of histologic
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1999, we recognized that less (or minimally) invasive surgery
with or without video assistance had been more generalized.5
In these minimally invasive techniques, the faster postoperative
recovery has been speculated, and this is a present-day trend in
oncologic surgery of any sites. Nevertheless, knowing that no
one study has ever definitely demonstrated that minimally inva-
sive surgery improves the survival of patients with lung cancer,
or the mortality/morbidity, it is unlikely that the improvement in
survival of the present registry population was solely because of
the advancements in surgical interventions.
Comparing the distribution of histologic types between
1994 and 1999, the 7% increase in adenocarcinomas and the
5% decrease in squamous cell carcinoma were remarkable
changes. In this registry study, the noninvasive form of
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FIGURE 8. Distribution of c-stage (A) and p-
stage (B) for non-small cell lung histologies in
1994 and 1999. The percentage of stage I in-
creased from 60 to 69% (11%) in the c-set-
ting, and from 52 to 59% (7%) in the p-set-
ting.
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adenocarcinoma, nonmucinous bronchioloalveolar carci-
noma, was included in the adenocarcinoma category. These
tumors are well known for their characteristic presentation on
high-resolution CT images as ground glass opacity and a
superb prognosis without recurrence after intervention.6,7
Considering that the evaluation of these faint, small-sized
tumors using high-resolution CT was being generalized in
Japan in late 1990s, the increase in bronchioloalveolar carci-
noma might have resulted in the inclusion of these earlier,
less-aggressive tumors into the registry population. The dis-
tribution of the stage of the disease at diagnosis also changed
remarkably between 1994 and 1999 as can be seen in Figure
8. The earliest disease, stage IA and IB, comprised 60% of
the c-stage and 52% of the p-stage in 1994, and 69% and 59%
in 1999, respectively. The shift of the patients’ diagnosis
toward an earlier staged disease at the time of surgery
definitely had a significant impact on the improvement in
overall survival.
Based on the second registry study of cases resected in
1994, we proposed a revision of the TNM staging system in
which the unification of stages IB and IIA and the division of
T1 into T1a and T1b by the cutoff length of a diameter of 2
cm were shown to be necessary. In this latest 1999 data set
the prognostic difference in survival between stages IB and
IIA was small. In the c-setting, the 5-year survival rates for IB
and IIA were 59.8% and 54.1%, and the difference in survival
was not statistically significant (p 0.1444). In the p-setting,
the 5-year survival rates for IB and IIA were 66.3% and
61.0%, and the difference in survival was marginally signif-
icant (p  0.0367), probably because of the increase in the
overall number of patients. Because the survival improve-
ment in patients with stage IB was so remarkable, the prog-
nostic difference between stages IB and IIA seemed to
increase in 1999 compared with that in 1994. Nevertheless,
considering the limited number of patients with stage IIA
disease, we believe that the unification of stages IB and IIA
would well characterize the stage-specific prognosis of both
groups.
In the report on the second registry study, the large
prognostic difference in survival by gender, age, and histol-
ogy was addressed. Also, in this third registry study, a
significant difference in survival according to these variables
was reproduced. Especially, the difference in 5-year survival
rate by gender was almost 20% in non-small cell carcinomas,
in which the 5-year survival rates for men and women were
55.5% and 74.5%, respectively. It is still unclear what factors
account for the large survival difference between men and
women. It is necessary to see the relationship between female
gender and other significant prognostic variables such as
histology and their biologic characteristics. Considering the
difference in smoking status between the two genders in
Japan, the difference in the biologic nature of cancers in
women versus men might have some impact on overall
survival.
The present retrospective, nationwide, large-scale reg-
istry study provides the most updated benchmark statistics for
patients with lung cancer. Further studies to elucidate the
factors associated with the improvement of survival and the
impact of several prognostic variables is underway.
REFERENCES
1. International Union Against Cancer. Lung tumours. In LH Sobin, CH
Wittekind (Eds.), TNM Classification of Malignant Tumours, 5th Ed.
New York: Wiley-Liss, 1997. Pp. 91–97.
2. Goya T, Asamura H, Yoshimura H, et al. Prognosis of 6644 resected
non-small cell lung cancers in Japan: a Japanese lung cancer registry
study. Lung Cancer 2005;50:227–234.
3. Asamura H, Goya T, Koshiishi Y, et al. How should the TNM staging
system for lung cancer be revised? A simulation based on the Japanese
Lung Cancer Registry populations. J Thorac Cardiovasc Surg 2006;132:
316–319.
4. Travis WD, Colby TV, Corrin B, et al. Histological Typing of Lung and
Pleural Tumors, World Health Organization International Histological
Classification of Tumors. Berlin, Germany: Springer, 1999.
5. McKenna RJ, Houck W, Fuller CB. Video-assisted thoracic surgery
lobectomy: experience with 1100 cases. Ann Thorac Surg 2006;81:421–
425.
6. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of
the lung. Histologic characteristics and prognosis. Cancer 1995;75:
2844–2852.
7. Sakurai H, Maeshima A, Watanabe S, et al. Grade of stromal invasion in
small adenocarcinoma of the lung: histopathological minimal invasion
and prognosis. Am J Surg Pathol 2004;28:198–206.
TABLE 3. Comparison of Stage-Specific 5-Yr Survival Rate
(%) between 1994 and 1999 (c-Stage) in Non-small Cell
Histologies
Year of Survey
c-Stage
All StagesIA IB IIA IIB IIIA IIIB IV
1994 (n  6,644) 72.1 49.9 48.7 40.6 35.8 28.0 20.8 52.6
1999 (n  12,620) 77.3 59.8 54.1 43.9 38.3 32.6 26.5 61.8
TABLE 4. Comparison of Stage-Specific 5-Yr Survival Rate
(%) between 1994 and 1999 (p-Stage) in Non-small Cell
Histologies
Year of Survey
p-Stage
All StagesIA IB IIA IIB IIIA IIIB IV
1994 (n  6,644) 79.5 60.1 59.9 42.2 29.8 19.3 20.0 52.6
1999 (n  12,620) 83.9 66.3 61.0 47.4 32.8 29.6 23.1 61.8
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